VIVUS News

For a variety of reasons the following biotech stocks may break-out if general Market conditions do not impede that possibility.

The Russell 3,000 is currently up 4.97% year to date, yet the average stock in the index is up 3.98% so far in 2012.

Going into a four-day weekend many traders do not like to hold stocks. Personally, I am 50/50 on this one as the extra day often times can help when faced with a choppy overall market that we are in now.

Without question, Threshold Pharmaceuticals, Inc. is on the cusp of becoming a blockbuster stock for those of you following the new developments, their pipeline, orphan drug status, EU approval, and discovery into Hypoxia and how it relates to cancer .

Yesterday, investors who placed their bets on Arena Pharma receiving a favorable recommendation from an FDA advisory committee on lorcaserin hit the small cap bio pharma jackpot.

Arena Pharmaceuticals Inc. won the backing of a U.S advisory panel for a weight-loss medicine competing to become the first obesity pill approved in 13 years.

THURSDAY, May 10 -- A new weight-loss drug that is awaiting approval from the U.S. Food and Drug Administration showed promising results in a recent international trial, researchers report.

Advisers to government health regulators on Thursday recommended that that they approve sales of what would be the first new prescription weight-loss drug in the U.S. in more than a decade, despite concerns over cardiac risks.

As widely expected, Arena Pharma's stock has been halted for trading until the results of a vote from an FDA advisory is known later today whether to recommend Arena's weight loss drug, lorcaserin to the FDA regulators for approval or rejection.

Vivus , a biotechnology company that focuses on obesity, diabetes and male sexual health is up roughly 150% year to date.

Investors hate to be limited, which is why a selection of choices is always better than just one.

Investors of Arena Pharmaceuticals could be twiddling their thumbs nervously over the next couple of days as lorcaserin -- the company's obesity drug candidate -- faces a crucial make-or-break review on May 10, 2012.

's stock had its "buy" rating reiterated by investment analysts at Needham & Company in a note issued to investors on Tuesday.

Obesity is fast becoming America's number one healthcare issue, eating up an increasingly gluttonous percentage of both the Medicare and Medicaid pie.

Shares of the following companies may have unusual moves in U.S. trading tomorrow.

Biopharmaceutical company Vivus is banking big on its newly approved pill that is expected to provide erections within 15 minutes, about half the time of Pfizer's A popular Viagra.

Many leading funds, including SAC Capital, MFS and GAMCO, filed forms 13-D and 13-G with the SEC on in the past week-and-a-half , indicating that they had amended their ownership in U.S. traded public companies.

On the morning of May 8th, the Food & Drug Administration will release the briefing documents for the May 10th Advisory Committee meeting to discuss the risk and benefit profile of Arena Pharmacueticals' new drug, Lorqess .

VIVUS, Inc. today announced that Timothy Morris, chief financial officer, will present an overview of the company at three investor conferences during the month of May.

On May 10, an FDA advisory committee will be trying to balance the effectiveness vs.